ABCC2 Polymorphism in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan, Fluorouracil and Leucovorin Chemotherapy
Keywords:
irinotecan, chemotherapy, ABCC2 polymorphisms, metastatic, colorectal cancerAbstract
Irinotecan is an anticancer medication used for the second-or third-line treatment of metastatic colorectal cancer. Several factors impact upon its effectiveness and toxicity, including ABCC2 polymorphisms. ABCC2 is responsible for irinotecan metabolism, especially in the excretion process. This study aimed to explore the prevalence of ABCC2 polymorphisms in Thai metastatic colorectal cancer treated with irinotecan, fluorouracil, and leucovorin chemotherapy regimen. Thirty-one patients were included in the study. The prevalence of ABCC2 (C>T) rs717620 was found to be 19.35%. Nineteen patients (61.3%) were C/C genotype and 12 patients (38.7%) were C/T. No patient in this study was T/T genotype. No treatment response or serious adverse events were associated with ABCC2 polymorphism. This study demonstrated that ABCC2 polymorphism was detectable in Thai metastatic colorectal cancer. Further study is needed to discover its impact, to improve treatment outcomes in irinotecan-based chemotherapy.
References
Hashim D, Boffetta P, La Vecchia C, Rota M, Bertuccio P, Malvezzi M, et al. The global decrease in cancer mortality: trends and disparities. Annals of oncology : official journal of the European Society for Medical Oncology. ESMO 2016;27:926-33.
Information Technology Division National Cancer Institute. Hospital-based cancer registry [Internet]. 2015. Available at: http://www.nci.go.th/th/File_download/Nci%20Cancer%20Registry/HOSPITALBASED%
pdf. Accessed Nov 20, 2017.
Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W, et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. pharmacogenomics J 2007;7:56-65.
Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, et al. Association of ATPbinding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull 2008;31: 2137-42.
Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, Poon D, et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 2005;59:415-24.
Akiyama Y, Fujita K-i, Ishida H, Sunakawa Y, Yamashita K, Kawara K, et al. Association of ABCC2 Genotype with Efficacy of First-line FOLFIRI in Japanese Patients with Advanced Colorectal Cancer. Drug Metab Pharmacokinet 2012;27:325-35.
Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 1997;57:1934-8.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
Tai CJ, Liu JH, Chen WS, Lin JK, Wang WS, Yen CC, et al. Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan. Jpn J Clin Oncol 2003;33:136-40.
de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, et al. Irinotecaninduced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007;81:42-9.
Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27:2604-14.
Downloads
Published
Issue
Section
License
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
